Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6667744 | 0.81 | — | — | |
| SCHEMBL1031474 | 0.81 | — | — | |
| SCHEMBL1032112 | 0.81 | — | — | |
| SCHEMBL8430261 | 0.81 | TP53 (0.41) | TP53 | |
| SCHEMBL11358364 | 0.74 | TP53 (0.38) | TP53SLC7A5 | |
| SCHEMBL27331253 | 0.74 | LMNA (0.30) | — | |
| SCHEMBL457721 | 0.74 | SLC7A5 (0.50) | TP53SLC7A5MAPT | |
| SCHEMBL1261744 | 0.74 | TP53 (0.50) | TP53SLC7A5 | |
| SCHEMBL18211012 | 0.74 | TP53 (0.50) | TP53SLC7A5 | |
| SCHEMBL812149 | 0.73 | TP53 (0.57) | TP53SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117441254-A | Electrolyte for secondary battery, and electronic device | 宁德新能源科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116706232-A | Electrolyte of secondary battery, secondary battery and electronic device | 宁德新能源科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-117832586-A | Electrochemical device and electronic device | 东莞新能源科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| CN-117441254-A | Electrolyte for secondary battery, and electronic device | 宁德新能源科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20240016895-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-112739753-B | Resin film and method for producing same | 东丽株式会社 | 2023-09-12 | — | — | CN | disclosed |
| CN-116706232-A | Electrolyte of secondary battery, secondary battery and electronic device | 宁德新能源科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116053591-B | Electrolyte of secondary battery, secondary battery and electronic device | 宁德新能源科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116053591-A | Electrolyte of secondary battery, secondary battery and electronic device | 宁德新能源科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20200361992-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018189-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | TP53 2998/4885SLC7A5 927/4885MAPT 4733/4885 |
| US-20200361992-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | TP53 2998/4885SLC7A5 927/4885MAPT 4733/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | TP53 2998/4885SLC7A5 927/4885MAPT 4733/4885 |
| US-20240016895-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | TP53 1738/4885SLC7A5 648/4885MAPT 4844/4885 |
| US-20240066131-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | TP53 2998/4885SLC7A5 927/4885MAPT 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.